Aβ-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer's mice

Neurobiology of Disease

Volumn 23, Issue 2, 2006, Pages 351-361

  Ethell, Douglas W ^a   Shippy, Daniel ^b   Cao, Chuanhai ^c   Cracchiolo, Jennifer R ^b   Runfeldt, Melissa ^b   Blake, Brett ^b   Arendash, Gary W ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Adoptive transfer; Alzheimer's disease; Beta amyloid; Cognitive impairment; Immunotherapy

Indexed keywords

AMYLOID BETA PROTEIN; CD4 ANTIGEN; OVALBUMIN; SYNAPTOPHYSIN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; HIPPOCAMPUS; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; MALE; MICROGLIA; MOUSE; NONHUMAN; PERFORMANCE; PRIORITY JOURNAL; SYNAPTIC TRANSMISSION; T CELL DEPLETION; T LYMPHOCYTE; TH1 CELL; TRANSGENIC MOUSE; VACCINATION; ANIMAL; COGNITION; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTE TRANSFUSION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNAPSE;

ADOPTIVE TRANSFER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; COGNITION; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; HUMANS; LYMPHOCYTE TRANSFUSION; MICE; MICE, TRANSGENIC; SYNAPSES; SYNAPTOPHYSIN; T-LYMPHOCYTES;

EID: 33746239693     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2006.03.008     Document Type: Article

References (32)

1. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., and Yednock T. Peripherally administered antibodies against amyloidβ-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nat. Med. 6 (2000) 916-919
2. Benner E.J., Mosley R.L., Destache C.J., Lewis T.B., Jackson-Lewis V., Gorantla S., Nemachek C., Green S.R., Przedborski S., and Gendelman H.E. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 9435-9440
3. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., and Ashe K.H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 8 (2005) 79-84
4. Costa D.A., Nilsson L.N., Bales K.R., Paul S.M., and Potter H. Apolipoprotein is required for the formation of filamentous amyloid, but not for amorphous Abeta deposition, in an AbetaPP/PS double transgenic mouse model of Alzheimer's disease. J. Alzheimer's Dis. 6 (2004) 509-514
5. Costello D.A., and Herron C.E. The role of c-Jun N-terminal kinase in the A beta-mediated impairment of LTP and regulation of synaptic transmission in the hippocampus. Neuropharmacology 46 (2004) 655-662
6. Cullen W.K., Suh Y.H., Anwyl R., and Rowan M.J. Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. NeuroReport 8 (1997) 3213-3217
7. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., DeLong C.A., Wu S., Wu X., Holtzman D.M., and Paul S.M. Immunization reduces memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5 (2002) 452-457
8. Ethell D.W., and Buhler L.A. Fas ligand-mediated apoptosis in degenerative disorders of the brain. J. Clin. Immunol. 23 (2003) 361-368
9. Ethell D.W., Kinloch R., and Green D.R. Metalloproteinase shedding of FasL regulates beta-amyloid neurotoxicity. Curr. Biol. 12 (2002) 1595-1600
10. Ferrer I., Boada-Rovira M., Sanchez-Guerra M.L., Rey M.J., and Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 14 (2004) 11-20
11. Furlan R., Brambilla E., Sanvito F., Roccatagliata L., Olivieri S., Bergami A., Pluchino S., Uccelli A., Comi G., and Martino G. Vaccination with amyloid-β peptide induces autoimmune encephalomyelitis in C57BL/6 mice. Brain 126 (2003) 285-291
12. Jensen M.T., Mottin M.D., Cracchiolo J.R., Leighty R.E., and Arendash G.W. Lifelong immunization with human β-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging. Neuroscience 130 (2005) 667-684
13. Kayed R., Brambilla E., Sanvito F., Roccatagliata L., Olivieri S., Bergami A., Pluchino S., Uccelli A., Comi G., and Martino G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003) 486-489
14. Klyubin I., Walsh D.M., Lemere C.A., Cullen W.K., Shankar G.M., Betts V., Spooner E.T., Jiang L., Anwyl R., Selkoe D.J., and Rowan M.J. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat. Med. 11 (2005) 556-561
15. Lee E.B., Leng L.Z., Lee V., and Trojanowski J.Q. Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis. FEBS Lett. 579 (2005) 2564-2568
16. Leighty R.E., Nilsson L.N., Potter H., Costa D.A., Low M.A., Bales K.R., Paul S.M., and Arendash G.W. Use of multimetric statistical analysis to characterize and discriminate between the performance or four Alzheimer's transgenic mouse lines differing in Aβ deposition. Brain Res. Reports 153 (2004) 107-121
17. Liberto C.M., Albrecht P.J., Herx L.M., Yong V.W., and Levison S.W. Pro-regenerative properties of cytokine-activated astrocytes. J. Neurochem. 89 (2004) 1092-1100
18. Monsonego A., and Weiner H.L. Immunotherapeutic approaches to Alzheimer's disease. Science 302 (2003) 834-838
19. Monsonego A., Maron R., Zota V., Selkoe D.J., and Weiner H.L. Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 10273-10278
20. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., and Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (2000) 982-985
21. Mungarro-Menchaca X., Ferrera P., Moran J., and Arias C. beta-Amyloid peptide induces ultrastructural changes in synaptosomes and potentiates mitochondrial dysfunction in the presence of ryanodine. J. Neurosci. Res. 68 (2002) 89-96
22. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B.F., Boada M., Frank A., and Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61 (2003) 46-54
23. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., and Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999) 173-177
24. Schmid C.D., Sautkulis L.N., Danielson P.E., Cooper J., Hasel K.W., Hilbush B.S., Sutcliffe J.G., and Carson M.J. Heterogeneous expression of the triggering receptor expressed on myeloid cells-2 on adult murine microglia. J. Neurochem. 83 (2002) 1309-1320
25. Schmidt S.D., Jiang Y., Nixon R.A., and Mathews P.M. Tissue processing prior to protein analysis and amyloid-β quantitation. In: Sigurdsson E.M. (Ed). Methods in Molecular Biology: Amyloid Proteins, Methods and Protocols (2005), Humana Press, Totowa, NJ
26. Schmidt S.D., Nixon R.A., and Mathews P.M. ELISA method for measurement of amyloid-β levels. In: Sigurdsson E.M. (Ed). Methods in Molecular Biology: Amyloid Proteins, Methods and Protocols (2005), Humana Press, Totowa, NJ
27. Sigurdsson E.M., Wisniewski T., and Frangione B. A safer vaccine for Alzheimer's Disease?. Neurobiol. Aging 23 (2002) 1001-1008
28. Tan J., Town T., Crawford F., Mori T., DelleDonne A., Crescentini R., Obregon D., Flavell R.A., and Mullan M.J. Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat. Neurosci. 5 (2002) 1288-1293
29. Tanzi R.E., and Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120 (2005) 545-555
30. Walsh D.M., and Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44 (2004) 181-193
31. Wilcock D.M., Rojiani A., Rosenthal A., Levkowitz G., Subbarao S., Alamed J., Wilson D., Wilson N., Freeman M.J., Gordon M.N., and Morgan D. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci. 24 (2004) 6144-6151
32. Wilcock D.M., Rojiani A., Rosenthal A., Subbarao S., Freeman M.J., Gordon M.N., and Morgan D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflammation 1 (2004) 24